Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS)
Chronic obstructive pulmonary disease (COPD) is associated with an increased risk of cardiovascular and cardiopulmonary events. In the phase III, 52-week ETHOS trial (NCT02465567), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF) reduced rates of moderate/severe exacerbations...
Gespeichert in:
| Veröffentlicht in: | American journal of respiratory and critical care medicine Jg. 211; H. 2; S. 205 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.02.2025
|
| Schlagworte: | |
| ISSN: | 1535-4970 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Chronic obstructive pulmonary disease (COPD) is associated with an increased risk of cardiovascular and cardiopulmonary events. In the phase III, 52-week ETHOS trial (NCT02465567), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF) reduced rates of moderate/severe exacerbations and all-cause mortality compared with dual therapy with glycopyrrolate/formoterol fumarate (GFF) or budesonide/formoterol fumarate (BFF). However, the effect of BGF on cardiovascular events versus GFF remains unevaluated. Furthermore, the effect of BGF on time to first severe exacerbation has not been reported.
To assess the effects of BGF 320/18/9.6 μg (BGF 320) and other inhaled corticosteroid-containing arms on cardiovascular and severe cardiopulmonary endpoints versus GFF in patients with COPD from the ETHOS trial.
Patients with moderate to very severe COPD and a history of exacerbations were randomized to twice-daily BGF 320, BGF 160/18/9.6 μg, BFF 320/9.6 μg, or GFF 18/9.6 μg (GFF). Time to first severe COPD exacerbation was a prespecified endpoint;
cardiovascular and severe cardiopulmonary endpoints included time to first major adverse cardiac event, time to first cardiovascular adverse event (AE) of special interest, time to first cardiac AE, and time to the composite endpoint of first severe cardiopulmonary event.
BGF 320 reduced the rate of first occurrence (hazard ratio [95% confidence interval]) of cardiovascular and severe cardiopulmonary events versus GFF, including for time to first cardiovascular adverse event of special interest (0.63 [0.48, 0.82]), cardiac AE (0.60 [0.48, 0.76]), and severe cardiopulmonary event (0.80 [0.67, 0.95]).
BGF had a benefit on cardiovascular endpoints and severe cardiopulmonary events versus GFF in patients with moderate to very severe COPD. |
|---|---|
| AbstractList | Chronic obstructive pulmonary disease (COPD) is associated with an increased risk of cardiovascular and cardiopulmonary events. In the phase III, 52-week ETHOS trial (NCT02465567), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF) reduced rates of moderate/severe exacerbations and all-cause mortality compared with dual therapy with glycopyrrolate/formoterol fumarate (GFF) or budesonide/formoterol fumarate (BFF). However, the effect of BGF on cardiovascular events versus GFF remains unevaluated. Furthermore, the effect of BGF on time to first severe exacerbation has not been reported.
To assess the effects of BGF 320/18/9.6 μg (BGF 320) and other inhaled corticosteroid-containing arms on cardiovascular and severe cardiopulmonary endpoints versus GFF in patients with COPD from the ETHOS trial.
Patients with moderate to very severe COPD and a history of exacerbations were randomized to twice-daily BGF 320, BGF 160/18/9.6 μg, BFF 320/9.6 μg, or GFF 18/9.6 μg (GFF). Time to first severe COPD exacerbation was a prespecified endpoint;
cardiovascular and severe cardiopulmonary endpoints included time to first major adverse cardiac event, time to first cardiovascular adverse event (AE) of special interest, time to first cardiac AE, and time to the composite endpoint of first severe cardiopulmonary event.
BGF 320 reduced the rate of first occurrence (hazard ratio [95% confidence interval]) of cardiovascular and severe cardiopulmonary events versus GFF, including for time to first cardiovascular adverse event of special interest (0.63 [0.48, 0.82]), cardiac AE (0.60 [0.48, 0.76]), and severe cardiopulmonary event (0.80 [0.67, 0.95]).
BGF had a benefit on cardiovascular endpoints and severe cardiopulmonary events versus GFF in patients with moderate to very severe COPD. |
| Author | Kisielewicz, Dobrawa Mushunje, Alec Arya, Niki Martinez, Fernando J Patel, Mehul Fredriksson, Martin Hurst, John R Ojili, Nikki Han, MeiLan K Bowen, Karin Gale, Chris P Movitz, Charlotta Parikh, Himanshu Singh, Dave |
| Author_xml | – sequence: 1 givenname: Dave orcidid: 0000-0001-8918-7075 surname: Singh fullname: Singh, Dave organization: Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester, United Kingdom – sequence: 2 givenname: Fernando J orcidid: 0000-0002-2412-3182 surname: Martinez fullname: Martinez, Fernando J organization: Division of Pulmonary, Allergy, and Critical Care Medicine, University of Massachusetts Chan, Worcester, Massachusetts – sequence: 3 givenname: John R orcidid: 0000-0002-7246-6040 surname: Hurst fullname: Hurst, John R organization: UCL Respiratory, University College London, London, United Kingdom – sequence: 4 givenname: MeiLan K orcidid: 0000-0002-9095-4419 surname: Han fullname: Han, MeiLan K organization: Division of Pulmonary and Critical Care, University of Michigan, Ann Arbor, Michigan – sequence: 5 givenname: Chris P orcidid: 0000-0003-4732-382X surname: Gale fullname: Gale, Chris P organization: Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom – sequence: 6 givenname: Martin surname: Fredriksson fullname: Fredriksson, Martin organization: AstraZeneca, Gothenburg, Sweden – sequence: 7 givenname: Dobrawa surname: Kisielewicz fullname: Kisielewicz, Dobrawa organization: AstraZeneca, Barcelona, Spain – sequence: 8 givenname: Alec surname: Mushunje fullname: Mushunje, Alec organization: AstraZeneca, Cambridge, United Kingdom – sequence: 9 givenname: Charlotta surname: Movitz fullname: Movitz, Charlotta organization: AstraZeneca, Gothenburg, Sweden – sequence: 10 givenname: Nikki surname: Ojili fullname: Ojili, Nikki organization: AstraZeneca, Gaithersburg, Maryland; and – sequence: 11 givenname: Himanshu surname: Parikh fullname: Parikh, Himanshu organization: AstraZeneca, Gaithersburg, Maryland; and – sequence: 12 givenname: Niki surname: Arya fullname: Arya, Niki organization: AstraZeneca, Durham, North Carolina – sequence: 13 givenname: Karin surname: Bowen fullname: Bowen, Karin organization: AstraZeneca, Gaithersburg, Maryland; and – sequence: 14 givenname: Mehul orcidid: 0000-0003-0435-858X surname: Patel fullname: Patel, Mehul organization: AstraZeneca, Cambridge, United Kingdom |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39213002$$D View this record in MEDLINE/PubMed |
| BookMark | eNo9UMtu2zAQJIIGeTU_0EOxxxaoEnIpS1ZvruLEAQLYaJxzQFIrmIVECqRkwPnCfFYZJO1lFoPd2Z2dc_bJeUeMfRH8Sogivw7G9FfIUQrMEoh1fcTOxEzOsrwq-Sk7j_EP5wLngp-wU1mhkJzjGXtdti2ZEXwL22CHjmC7o6CGA3gHtQqN9XsVzdSpAMo18Eh7CvTRGaau906FAyz35MYINml2wTtrYK3jGCYz2j3B5v_cjY2kIv2EBWx8HGHlDSyc6g7RxjcPCn6nK763L9T8gBs_6Y6yX511iW12SQkS6kStUd2b4YTfltvV-vH7Z3bcqi7S5Ue9YE-3y229yh7Wd_f14iEzssjHTCiUheaEjVFtXuiyLFHmqLhGnOVY6HlV6ZLKsqmadl5RNWt5iVrJAlN4Zo4X7Ov73mHSPTXPQ7B9-uz5X6T4F0WteuQ |
| CitedBy_id | crossref_primary_10_1007_s40265_025_02188_8 crossref_primary_10_1136_thorax_2025_223459 crossref_primary_10_1016_j_semerg_2025_102478 crossref_primary_10_1164_rccm_202410_1922LE crossref_primary_10_1080_03007995_2025_2545493 crossref_primary_10_1164_rccm_202409_1842LE crossref_primary_10_1007_s12325_025_03361_x crossref_primary_10_1253_circj_CJ_24_1025 crossref_primary_10_1164_rccm_202407_1494ED crossref_primary_10_1055_a_2326_7636 crossref_primary_10_1164_rccm_202410_1945LE |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM |
| DOI | 10.1164/rccm.202312-2311OC |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
| DatabaseTitleList | MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1535-4970 |
| ExternalDocumentID | 39213002 |
| Genre | Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Journal Article |
| GrantInformation_xml | – fundername: AstraZeneca |
| GroupedDBID | --- -~X .55 .GJ 0R~ 1CY 1KJ 23M 2WC 34G 39C 3O- 53G 5GY 5RE 7RV 7X7 88E 8AO 8C1 8FI 8FJ 8FW 8R4 8R5 AAEJM AAQQT AAWTL ABJNI ABOCM ABPMR ABUWG ACBNA ACGFO ACGFS ADBBV AENEX AFCHL AFFNX AFKRA AFUWQ AHMBA AI. AJJEV ALIPV ALMA_UNASSIGNED_HOLDINGS AN0 BAWUL BENPR BKEYQ BNQBC BPHCQ BVXVI C45 CCPQU CGR CS3 CUY CVF DIK E3Z EBS ECM EIF EJD EMOBN EX3 F5P FRP FYUFA GX1 H13 HMCUK HZ~ IH2 J5H KQ8 L7B M1P M5~ N4W NAPCQ NPM O9- OBH OFXIZ OGEVE OHT OK1 OVD OVIDX P2P PCD PHGZM PHGZT PMFND PQQKQ PROAC PSQYO Q2X RWL SJN TAE TEORI THO TR2 UKHRP VH1 W8F WH7 WOQ WOW X7M YJK ZE2 ZGI ZXP ~02 |
| ID | FETCH-LOGICAL-c364t-1a236b0e2dcaf46b7772342a0b225426b899b7e77d9df89e95f072ba362128c82 |
| ISICitedReferencesCount | 15 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001461570500013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| IngestDate | Fri May 30 10:59:46 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | mortality budesonide/glycopyrrolate/formoterol fumarate hospitalization cardiovascular |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c364t-1a236b0e2dcaf46b7772342a0b225426b899b7e77d9df89e95f072ba362128c82 |
| ORCID | 0000-0003-4732-382X 0000-0002-7246-6040 0000-0001-8918-7075 0000-0002-2412-3182 0000-0002-9095-4419 0000-0003-0435-858X |
| PMID | 39213002 |
| ParticipantIDs | pubmed_primary_39213002 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-Feb |
| PublicationDateYYYYMMDD | 2025-02-01 |
| PublicationDate_xml | – month: 02 year: 2025 text: 2025-Feb |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | American journal of respiratory and critical care medicine |
| PublicationTitleAlternate | Am J Respir Crit Care Med |
| PublicationYear | 2025 |
| References | 39255455 - Am J Respir Crit Care Med. 2025 Feb;211(2):142-143. doi: 10.1164/rccm.202407-1494ED. |
| References_xml | – reference: 39255455 - Am J Respir Crit Care Med. 2025 Feb;211(2):142-143. doi: 10.1164/rccm.202407-1494ED. |
| SSID | ssj0012810 |
| Score | 2.541089 |
| Snippet | Chronic obstructive pulmonary disease (COPD) is associated with an increased risk of cardiovascular and cardiopulmonary events. In the phase III, 52-week ETHOS... |
| SourceID | pubmed |
| SourceType | Index Database |
| StartPage | 205 |
| SubjectTerms | Administration, Inhalation Aged Bronchodilator Agents - administration & dosage Bronchodilator Agents - therapeutic use Budesonide - administration & dosage Budesonide - therapeutic use Cardiovascular Diseases - etiology Cardiovascular Diseases - prevention & control Double-Blind Method Drug Therapy, Combination Female Formoterol Fumarate - administration & dosage Formoterol Fumarate - therapeutic use Glycopyrrolate - administration & dosage Glycopyrrolate - therapeutic use Humans Male Middle Aged Pulmonary Disease, Chronic Obstructive - complications Pulmonary Disease, Chronic Obstructive - drug therapy Severity of Illness Index Treatment Outcome |
| Title | Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS) |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39213002 |
| Volume | 211 |
| WOSCitedRecordID | wos001461570500013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtZ1Lb9NAEMdXDaCql6q8WwqaAweQa-GsH2tzKyEoEpCi1ki9VV57V7WU2pHbRhWfkI_F7KtxAgg4cLESb-JsND_tzO7-Z5aQl0kVhWkppC8rxv2I8cznMgx9jN0ljQXOObJKHzbBptP09DT7sjGgLhdmMWNNk97cZPP_amq8h8ZWqbP_YO7bh-INfI1GxyuaHa9_ZXhbjxiDwLzTUsHcFA5Q2wKjVfWplm0K_IfCtsyvZ9hPJaQbL3Tqm8oJNOVzvSNua80ulMjHfe692eAxCe7q5F9v0pYrpU4K7xh_p72ov5l1VQzZ-Uz47zC-NTHsOX7fC72Ry9HM9UEiGPmO88nRiVuqcJVy3Q5Tr-RF15ML6DQ9d3yDlrWtqwdO0FmfWzl_T_irqimY1XS7tN4ud8wm151JjdE6o-PlqG2E0KL-hB362F9AobHTXCv_5wb9WJ20F_S9ArU-oO7Nzu0Yr_PEf-F7kgjZ6MpSFTjAsJn6eBma0pw97uYXGjyMS9VOIv1z61o9cNc0IAOWKFc0VetTdt-MpsPApYYl0ZufO7NFNt0D1iZSOqDKd8i2nQnBoSH4PtkQzQOy-dla6yH5bkCGVoIBGSzI0DawCjKgucCADGsggwEZavyOARl6IMMtyGBBfguHoDAGxBgcxqoPBSwxPoA-xAegEYYQHMKgEYZXGuDXj8jXD-N8NPHtuSN-GSbRlT8saJjwQNCqLGSUcIYz0DCiRcDR-WFEy9Ms40wwVmWVTDORxTJglBcYC6IBypQ-JneathFPCeAQKYZxIoXEODpM8W0kZSWrWMZFLIJklzwxNjibm-IyZ846e79teUa2lhjvk7sSBy7xnNwrF1f1ZfdCA_EDjLK_lA |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+Triple+Therapy+on+Cardiovascular+and+Severe+Cardiopulmonary+Events+in+Chronic+Obstructive+Pulmonary+Disease%3A+A+Post+Hoc+Analysis+of+a+Randomized%2C+Double-Blind%2C+Phase+3+Clinical+Trial+%28ETHOS%29&rft.jtitle=American+journal+of+respiratory+and+critical+care+medicine&rft.au=Singh%2C+Dave&rft.au=Martinez%2C+Fernando+J&rft.au=Hurst%2C+John+R&rft.au=Han%2C+MeiLan+K&rft.date=2025-02-01&rft.eissn=1535-4970&rft.volume=211&rft.issue=2&rft.spage=205&rft_id=info:doi/10.1164%2Frccm.202312-2311OC&rft_id=info%3Apmid%2F39213002&rft_id=info%3Apmid%2F39213002&rft.externalDocID=39213002 |